Join us for coffee and a chat about healthy aging
Coffee and a Chat, a free, virtual event series. Join in from home – by computer or phone – and listen to health experts and ask questions.
Coffee and a Chat, a free, virtual event series. Join in from home – by computer or phone – and listen to health experts and ask questions.
First-year medical students are invited to apply today.
Dr. Mora Pinzon’s work focuses on health services research in dementia care, and improving access to dementia care for Latinx individuals.
On a recent episode of the Dementia Matters podcast, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.
Cynthia Carlsson, MD, MS, was recently interviewed by CBS 58 News in Milwaukee about the U.S. Food and Drug Administration (FDA) approval of Leqembi (lecanemab), which showed a reduction of clinical decline in a study of people with early Alzheimer’s disease. “What was impressive about this study is that it improved the amyloid levels in …
On January 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing …
How sweet the sound at a live, in person concert on December 17.
Congratulations, Dr. Johnson!
Event features updates in dementia care and research. Thank you to our speakers and attendees!
Experimental drug shows reduction of cognitive decline in people living with early Alzheimer’s disease. Same drug is currently used in AHEAD study at UW.